Literature DB >> 10746632

Characterization of human and rat glucagon-like peptide-1 receptors in the neurointermediate lobe: lack of coupling to either stimulation or inhibition of adenylyl cyclase.

F Satoh1, S A Beak, C J Small, M Falzon, M A Ghatei, S R Bloom, D M Smith.   

Abstract

Glucagon-like peptide-1 (GLP-1) has been shown to bind to the posterior pituitary in the rat. We examined GLP-1 binding sites in human postmortem and rat pituitaries. Dense [125I]GLP-1 binding was seen in both human and rat posterior pituitary. In rat neurointermediate lobe membranes the binding site showed a Kd of 0.2 +/- 0.01 nM and a binding capacity of 600 +/- 33 fmol/mg protein (n = 3). In human pituitary membranes the binding site showed a Kd of 0.82 +/-0.05 nM and a binding capacity of 680 +/- 93 fmol/mg protein (n = 3). Chemical cross-linking showed a relative mol wt for the receptor-ligand complex of 73,100 +/- 1,400 (n = 3) in man and 59,300 +/- 900 (n = 3) in rat. GLP-1 (1 microM) failed to increase cAMP levels measured in rat neurointermediate lobes, whereas pituitary adenylate cyclase-activating polypeptide (100 nM) increased cAMP from a basal level of 14 +/-1 to 80 +/- 4 pmol/neurointermediate lobe 15 min (n = 5; P < 0.01). GLP-1 (up to 1 microM) did not affect the pituitary adenylate cyclase-activating polypeptide-stimulated cAMP levels. GLP-1 (up to 1 microM) also did not stimulate release of vasopressin or oxytocin from isolated rat neurointermediate lobes. The posterior pituitary shows the highest density of GLP-1-binding sites yet seen, but their function and signal transduction mechanism remain unknown.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10746632     DOI: 10.1210/endo.141.4.7420

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  16 in total

Review 1.  Is Glucagon-like peptide-1, an agent treating diabetes, a new hope for Alzheimer's disease?

Authors:  Lin Li
Journal:  Neurosci Bull       Date:  2007-01       Impact factor: 5.203

Review 2.  Evidence for central regulation of glucose metabolism.

Authors:  Michelle Carey; Sylvia Kehlenbrink; Meredith Hawkins
Journal:  J Biol Chem       Date:  2013-10-18       Impact factor: 5.157

Review 3.  Glucagon-Like Peptide-1 and Its Class B G Protein-Coupled Receptors: A Long March to Therapeutic Successes.

Authors:  Chris de Graaf; Dan Donnelly; Denise Wootten; Jesper Lau; Patrick M Sexton; Laurence J Miller; Jung-Mo Ahn; Jiayu Liao; Madeleine M Fletcher; Dehua Yang; Alastair J H Brown; Caihong Zhou; Jiejie Deng; Ming-Wei Wang
Journal:  Pharmacol Rev       Date:  2016-10       Impact factor: 25.468

Review 4.  The effect of glucagon-like peptide 1 on cardiovascular risk.

Authors:  Jacob Sivertsen; Jaya Rosenmeier; Jens J Holst; Tina Vilsbøll
Journal:  Nat Rev Cardiol       Date:  2012-01-31       Impact factor: 32.419

5.  Target-mediated pharmacokinetic and pharmacodynamic model of exendin-4 in rats, monkeys, and humans.

Authors:  Wei Gao; William J Jusko
Journal:  Drug Metab Dispos       Date:  2012-02-15       Impact factor: 3.922

6.  Pharmacokinetic and pharmacodynamic modeling of exendin-4 in type 2 diabetic Goto-Kakizaki rats.

Authors:  Wei Gao; William J Jusko
Journal:  J Pharmacol Exp Ther       Date:  2010-12-14       Impact factor: 4.030

7.  Evidence of GLP-1-mediated neuroprotection in an animal model of pyridoxine-induced peripheral sensory neuropathy.

Authors:  TracyAnn Perry; Harold W Holloway; Ananda Weerasuriya; Peter R Mouton; Kara Duffy; Julie A Mattison; Nigel H Greig
Journal:  Exp Neurol       Date:  2006-11-22       Impact factor: 5.330

8.  Interspecies modeling and prediction of human exenatide pharmacokinetics.

Authors:  Ting Chen; Donald E Mager; Leonid Kagan
Journal:  Pharm Res       Date:  2012-11-15       Impact factor: 4.200

9.  Glucagon-like peptide-1 (GLP-1) diminishes neuronal degeneration and death caused by NGF deprivation by suppressing Bim induction.

Authors:  Subhas C Biswas; Jean Buteau; Lloyd A Greene
Journal:  Neurochem Res       Date:  2008-03-20       Impact factor: 3.996

Review 10.  Antidiabetic treatment, stroke severity and outcome.

Authors:  Dimitra Magkou; Konstantinos Tziomalos
Journal:  World J Diabetes       Date:  2014-04-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.